EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC 4.0

Effects of nintedanib on symptoms in patients with progressive pulmonary fibrosis

Marlies Wijsenbeek, Jeffrey J Swigris, Yoshikazu Inoue iD, Michael Kreuter, Toby M Maher, Takafumi Suda, Michael Baldwin, Heiko Mueller, Klaus B Rohr, Kevin R Flaherty, INBUILD Trial Investigators

European Respiratory Journal · 2024

DOI: 10.1183/13993003.00752-2023 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift European Respiratory Journal, 2024. Verfasst von Marlies Wijsenbeek und 10 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Interstitial Lung Diseases and Sarcoidosis, Department of Respiratory Medicine, Erasmus MC, University Medical Centre, Rotterdam, The Neth…. Hauptthemen laut MEDLINE: Lung Diseases, Interstitial, Idiopathic Pulmonary Fibrosis, Indoles. Die Arbeit wurde bisher 59-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Boehringer Ingelheim.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Dyspnoea and cough can have a profound impact on the lives of patients with pulmonary fibrosis. We investigated the effects of nintedanib on the symptoms and impact of pulmonary fibrosis in patients with progressive pulmonary fibrosis (PPF) in the INBUILD trial using the Living with Pulmonary Fibrosis (L-PF) questionnaire.

Methods

Patients had a fibrosing interstitial lung disease (ILD) (other than idiopathic pulmonary fibrosis) of >10% extent on high-resolution computed tomography (HRCT) and met criteria for ILD progression within the prior 24 months. Patients were randomised 1:1 to receive nintedanib or placebo. Changes in L-PF questionnaire scores from baseline to week 52 were assessed using mixed models for repeated measures.

Results

In total, 663 patients were treated. Compared with placebo, there were significantly smaller increases (worsenings) in adjusted mean L-PF questionnaire total (0.5 versus 5.1), symptoms (1.3 versus 5.3), dyspnoea (4.3 versus 7.8) and fatigue (0.7 versus 4.0) scores in the nintedanib group at week 52. L-PF questionnaire cough score decreased in the nintedanib group and increased in the placebo group (−1.8 versus 4.3). L-PF questionnaire impacts score decreased slightly in the nintedanib group and increased in the placebo group (−0.2 versus 4.6). Similar findings were observed in patients with a usual interstitial pneumonia-like fibrotic pattern on HRCT and in patients with other fibrotic patterns on HRCT.

Conclusion

Based on changes in L-PF questionnaire scores, nintedanib reduced worsening of dyspnoea, fatigue and cough and the impacts of ILD over 52 weeks in patients with PPF.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung Diseases, InterstitialIdiopathic Pulmonary FibrosisIndolesHumansVital CapacityDisease ProgressionFibrosisDyspneaCoughDouble-Blind Method

Substanzen

nintedanibIndoles

Autor:innen und Institutionen

  • Centre for Interstitial Lung Diseases and Sarcoidosis, Department of Respiratory Medicine, Erasmus MC, University Medical Centre, Rotterdam, The Netherlands m.wijsenbeek-lourens@erasmusmc.nl.
  • National Jewish Health, Denver, CO, USA.
  • National Hospital Organization Kinki-Chuo Chest Medical Center, Osaka, Japan.
  • Center for Pulmonary Medicine, Department of Pneumology, Mainz University Medical Center, Mainz, Germany.
  • Pulmonary, Critical Care and Sleep Medicine, Marienhaus Clinic Mainz, Mainz, Germany.
  • Inflammation, Repair and Development Section, National Heart and Lung Institute, Imperial College London, London, UK.

ORCID-Profile: Yoshikazu Inoue

Förderung

  • Boehringer Ingelheim

Zitieren

APA

Wijsenbeek, M., Swigris, J. J., Inoue, Y., Kreuter, M., Maher, T. M., Suda, T., Baldwin, M., Mueller, H., Rohr, K. B., Flaherty, K. R., & INBUILD Trial Investigators (2024). Effects of nintedanib on symptoms in patients with progressive pulmonary fibrosis. European Respiratory Journal. https://doi.org/10.1183/13993003.00752-2023

Vancouver

Wijsenbeek M, Swigris JJ, Inoue Y, Kreuter M, Maher TM, Suda T, et al. Effects of nintedanib on symptoms in patients with progressive pulmonary fibrosis. European Respiratory Journal. 2024. doi:10.1183/13993003.00752-2023

BibTeX
@article{Wijsenbeek2024,
  author = {Wijsenbeek, Marlies and Swigris, Jeffrey J and Inoue, Yoshikazu and Kreuter, Michael and Maher, Toby M and Suda, Takafumi and Baldwin, Michael and Mueller, Heiko and Rohr, Klaus B and Flaherty, Kevin R and INBUILD Trial Investigators, INBUILD Trial Investigators},
  title = {Effects of nintedanib on symptoms in patients with progressive pulmonary fibrosis},
  journal = {European Respiratory Journal},
  year = {2024},
  doi = {10.1183/13993003.00752-2023}
}
Kostenlos starten →